TLDR
- JSPR climbs after briquilimab shows strong gains in asthma trial data.
- Fresh asthma trial success sends JSPR higher with promising outcomes.
- Briquilimab boosts lung function as JSPR posts key trial progress.
- JSPR rises as new asthma study confirms briquilimab’s clinical strength.
- Strong asthma results push JSPR upward with renewed development momentum.
Jasper Therapeutics, Inc. (JSPR) traded at $1.7742 as of 12:58 PM EST, marking a 3.16% increase.
Jasper Therapeutics, Inc., JSPR
JSPR opened with volatility and hit a sharp premarket peak before gradually easing through the session. Despite the pullback, JSPR remained above its starting price, driven by fresh clinical trial results.
The company released encouraging preliminary data from its Phase 1b ETESIAN study evaluating briquilimab in asthma patients. JSPR reported that the single 180mg dose of briquilimab showed significant improvements in lung function and reduced airway inflammation. The stock responded to the results with renewed momentum and continued market attention.
JSPR is a clinical-stage biotech company focused on targeting KIT (CD117) to treat mast cell-driven diseases. Its lead candidate, briquilimab, is in development for chronic spontaneous urticaria, inducible urticaria, and asthma. The recent data adds validation to JSPR’s approach, strengthening its clinical narrative.
Briquilimab Shows Strong Efficacy in Asthma Patients
In the ETESIAN trial, JSPR evaluated a single 180mg subcutaneous dose of briquilimab in 14 patients. The study showed notable reductions in sputum eosinophils and consistent improvement in lung function through FEV1 measures. The treatment led to better resistance to methacholine, signaling improved airway responsiveness.
JSPR emphasized that the improvements in Early and Late Asthmatic Responses remained steady at weeks 6 and 12. Compared to placebo, the briquilimab-treated group recorded a 25.4% and 23.3% drop in airway obstruction metrics. These findings strengthen the company’s claim that mast cell depletion could offer therapeutic benefits for asthma.
JSPR also highlighted that briquilimab maintained a favorable safety profile throughout the trial. There were no dose-limiting toxicities, and reported side effects were mild and infrequent. The data supports the continued development of briquilimab in respiratory indications.
BEACON Cohort Anomaly Traced to Patient Selection
JSPR concluded its internal review of anomalies from the July 2025 BEACON study results. In that study, cohorts 8 and 9 showed no clinical response in 10 U.S. patients. JSPR has now confirmed that drug quality was not the issue.
The company determined that 9 of the 10 participants likely did not have mast cell-driven CSU. Despite poor clinical outcomes, patients still showed expected pharmacodynamic responses, further verifying the drug’s mechanism. These insights have informed updated patient selection protocols going forward.
JSPR stated that it switched patients to a new drug lot and analyzed all relevant manufacturing and clinical data. The company also consulted a panel of clinical experts to review and validate the findings. The resolution paves the way for JSPR to finalize dosing plans for its Phase 2b CSU trial in 2026.
JSPR Advances Briquilimab Pipeline Amid Positive Momentum
With ETESIAN data in hand, JSPR will plan broader studies to explore briquilimab’s full potential in asthma. The company now has both proof-of-concept data and a strong safety record across multiple studies. These milestones could position JSPR for a pivotal role in managing mast cell-driven diseases.
JSPR’s leadership expressed confidence in briquilimab’s potential and the integrity of its clinical development process. The company remains focused on meeting unmet medical needs through mast cell targeting. As JSPR progresses, the stock’s performance will likely reflect continued clinical advancements.
JSPR continues to build value through precision immunology, and the latest trial results reinforce its pipeline strength. Briquilimab remains the centerpiece of JSPR’s therapeutic strategy. This momentum could translate into expanded trials and broader applications.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
